Polymer-Encapsulated Oral Dosage Forms for Sensitive API Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of sensitive APIs in semi-solid oral dosage forms like gummies and oral thin films is constrained by stability issues due to water, acidity, oxygen, and UV exposure, leading to rapid degradation and reduced potency, and taste masking is challenging for APIs with unpleasant flavors.
Innovation Solution
A tailored encapsulation step using polymers to isolate APIs from destabilizing agents, providing a protective barrier that maintains chemical and physical stability and masks taste.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If sensitive APIs are incorporated into semi-solid oral dosage forms, then patient compliance and ease of administration are improved, but API stability deteriorates due to exposure to water, acid, oxygen, and UV light
Solution Approach 1:
The patent segments the API from the destabilizing environment by incorporating it into separate encapsulated units within the semi-solid dosage form. Each API is enclosed in an individual capsule or microencapsulated structure, physically separating it from water, acid, oxygen, and UV light in the matrix, thereby maintaining stability while preserving the ease of administration of the overall dosage form.
Solution Approach 2:
The patent introduces an intermediary encapsulation layer between the API and the destabilizing excipients in the semi-solid matrix. This intermediary barrier (capsule shell, coating, or microencapsulation layer) prevents direct contact between the API and harmful agents while allowing the semi-solid form to maintain its palatable and easy-to-administer characteristics.
2Reliability
If APIs with unpleasant tastes are used, then therapeutic efficacy is maintained, but patient acceptability deteriorates due to taste masking challenges
Solution Approach 1:
The patent extracts the API from direct exposure to the oral cavity environment by encapsulating it. The encapsulated API is released in a controlled manner, separating the unpleasant taste from the therapeutic action. This allows maintenance of therapeutic efficacy while improving patient acceptability, as the taste issue is resolved by the encapsulation barrier rather than requiring extensive flavor masking.
3Stability of the object's composition
If conventional stabilization methods such as enteric coatings are used, then API stability is improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent employs a universal encapsulation approach that simultaneously provides multiple functions: protection from water, acid, oxygen, and UV light, plus taste masking and controlled release. This multi-functional encapsulation system achieves API stability without requiring separate enteric coatings or multiple stabilization layers, thereby reducing overall formulation complexity compared to conventional multi-step stabilization methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The encapsulation strategy effectively stabilizes sensitive APIs during manufacturing and storage, enhancing potency and patient acceptability without the need for excessive additives, expanding the range of usable APIs in semi-solid formats.
Implementation Method 1
The polymer encapsulates at least a portion of the active ingredient, the portion of the active ingredient that is encapsulated does not come in direct contact with the one or more excipients
Data Source
AI summary
A semi-solid oral dosage form that includes one or more excipients, an active ingredient, and a polymer. The polymer encapsulates at least a portion of the active ingredient, and the portion of the active ingredient that is encapsulated does not come in direct contact with the one or more excipients present in the semi-solid oral dosage form. The semi-solid oral dosage form can be, e.g., an oral thin film (OTF) or gummy. Also provided is a method of orally administering the semi-solid oral dosage form, as well as methods of manufacturing the semi-solid oral dosage form.